These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 17069803

  • 41. Evaluating the evidence for multiple sclerosis as an autoimmune disease.
    Altmann D.
    Arch Neurol; 2005 Apr; 62(4):688; author reply 688-9. PubMed ID: 15824275
    [No Abstract] [Full Text] [Related]

  • 42. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.
    J Immunol Methods; 2007 Apr 10; 321(1-2):19-31. PubMed ID: 17335844
    [Abstract] [Full Text] [Related]

  • 43. Mitoxantrone in multiple sclerosis.
    Neuhaus O, Kieseier BC, Hartung HP.
    Adv Neurol; 2006 Apr 10; 98():293-302. PubMed ID: 16400840
    [No Abstract] [Full Text] [Related]

  • 44. [Multiple sclerosis].
    Offenhäusser M, Martin R.
    Med Monatsschr Pharm; 1997 Jun 10; 20(6):149-57. PubMed ID: 9289627
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: clinical and histopathological evaluation.
    Stojkov D, Lavrnja I, Pekovic S, Dacic S, Bjelobaba I, Mostarica-Stojkovic M, Stosic-Grujicic S, Jovanovic S, Nedeljkovic N, Rakic L, Stojiljkovic M.
    J Neurol Sci; 2008 Apr 15; 267(1-2):76-85. PubMed ID: 17996253
    [Abstract] [Full Text] [Related]

  • 47. The impact of interferon-beta treatment on the blood-brain barrier.
    Kraus J, Oschmann P.
    Drug Discov Today; 2006 Aug 15; 11(15-16):755-62. PubMed ID: 16846804
    [Abstract] [Full Text] [Related]

  • 48. The gap between effect of drugs and effectiveness of treatments.
    Sorensen PS.
    J Neurol Sci; 2007 Aug 15; 259(1-2):128-32. PubMed ID: 17362994
    [Abstract] [Full Text] [Related]

  • 49. [Multiple sclerosis in children].
    Neuteboom RF, Catsman-Berrevoets CE, Hintzen RQ.
    Ned Tijdschr Geneeskd; 2007 Jun 30; 151(26):1464-8. PubMed ID: 17633977
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B, Hartung HP.
    Ann Neurol; 2007 Oct 30; 62(4):314-26. PubMed ID: 17969020
    [Abstract] [Full Text] [Related]

  • 52. Combining two multiple sclerosis treatments has no clinical benefit, study finds.
    Anekwe L.
    BMJ; 2013 Mar 14; 346():f1719. PubMed ID: 23491460
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Multiple sclerosis: where will we be in 2020?
    Miller AE.
    Mt Sinai J Med; 2011 Mar 14; 78(2):268-79. PubMed ID: 21425270
    [Abstract] [Full Text] [Related]

  • 58. [Long-term prevention of MS: effectiveness alone is not enough].
    Haas J.
    Krankenpfl J; 2005 Mar 14; 43(7-10):237. PubMed ID: 16515307
    [No Abstract] [Full Text] [Related]

  • 59. [Has it been indicated already to use beta-interferon in patients with multiple sclerosis?].
    Fernández O.
    Rev Neurol; 1995 Mar 14; 23(123):986-90. PubMed ID: 8556611
    [No Abstract] [Full Text] [Related]

  • 60. Neuroprotection in multiple sclerosis.
    Karussis D, Grigoriadis S, Polyzoidou E, Grigoriadis N, Slavin S, Abramsky O.
    Clin Neurol Neurosurg; 2006 Mar 14; 108(3):250-4. PubMed ID: 16413962
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.